ATE502958T1 - Gegen inaktivierung resistenter faktor viii - Google Patents

Gegen inaktivierung resistenter faktor viii

Info

Publication number
ATE502958T1
ATE502958T1 AT06004484T AT06004484T ATE502958T1 AT E502958 T1 ATE502958 T1 AT E502958T1 AT 06004484 T AT06004484 T AT 06004484T AT 06004484 T AT06004484 T AT 06004484T AT E502958 T1 ATE502958 T1 AT E502958T1
Authority
AT
Austria
Prior art keywords
acid sequences
sequences
proteins
amino acid
nucleic acid
Prior art date
Application number
AT06004484T
Other languages
German (de)
English (en)
Inventor
Randal J Kaufman
Steven W Pipe
Kagehiro Amano
Original Assignee
Univ Michigan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Michigan filed Critical Univ Michigan
Application granted granted Critical
Publication of ATE502958T1 publication Critical patent/ATE502958T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT06004484T 1996-04-24 1997-04-24 Gegen inaktivierung resistenter faktor viii ATE502958T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1611796P 1996-04-24 1996-04-24
US1778596P 1996-05-15 1996-05-15

Publications (1)

Publication Number Publication Date
ATE502958T1 true ATE502958T1 (de) 2011-04-15

Family

ID=26688196

Family Applications (2)

Application Number Title Priority Date Filing Date
AT06004484T ATE502958T1 (de) 1996-04-24 1997-04-24 Gegen inaktivierung resistenter faktor viii
AT97927596T ATE319817T1 (de) 1996-04-24 1997-04-24 Gegen inaktivierung resistenter faktor viii

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT97927596T ATE319817T1 (de) 1996-04-24 1997-04-24 Gegen inaktivierung resistenter faktor viii

Country Status (10)

Country Link
US (2) US6838437B2 (ref)
EP (3) EP0910628B1 (ref)
JP (2) JP3987114B2 (ref)
AT (2) ATE502958T1 (ref)
AU (1) AU3202797A (ref)
CA (1) CA2252896C (ref)
DE (2) DE69735421T2 (ref)
DK (1) DK1754718T3 (ref)
PT (1) PT1754718E (ref)
WO (1) WO1997040145A1 (ref)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0833848T3 (da) * 1995-06-12 2001-11-05 Sanquin Bloedvoorziening Faktor IX-bindende peptider afledt af faktor VIII og anvendelse heraf som inhibitorer af blodkoagulation
CA2252896C (en) 1996-04-24 2009-03-10 The Regents Of The University Of Michigan Inactivation resistant factor viii
US8183344B2 (en) 1996-04-24 2012-05-22 University Of Michigan Inactivation resistant factor VIII
US20040092442A1 (en) * 1996-04-24 2004-05-13 University Of Michigan Inactivation resistant factor VIII
WO1999041385A1 (en) * 1998-02-13 1999-08-19 Cadus Pharmaceutical Corporation Mekk1 proteins and fragments thereof for use in regulating apoptosis
EP1351986A2 (en) * 2001-01-12 2003-10-15 The American National Red Cross Methods and compositions for reducing heparan sulfate proteoglycan-mediated clearance of factor viii
US7211558B2 (en) * 2002-05-22 2007-05-01 The Children's Hospital Of Philadelphia Compositions and methods for the treatment of hemophilia A
US7041635B2 (en) * 2003-01-28 2006-05-09 In2Gen Co., Ltd. Factor VIII polypeptide
EP1502921A1 (en) * 2003-07-29 2005-02-02 ZLB Behring GmbH Recombinant mutated human factor VIII (FVIII) with improved stability
JP2008525381A (ja) * 2004-12-23 2008-07-17 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト 関心のあるビタミンｋ依存性タンパク質を含んでなる組成物中におけるタンパク質混入物の量の減少
KR20080007226A (ko) * 2005-04-14 2008-01-17 체에스엘 베링 게엠베하 증가된 안정성을 가진 변형된 응고 인자 ⅷ 및 이의 유도체
EP1816201A1 (en) 2006-02-06 2007-08-08 CSL Behring GmbH Modified coagulation factor VIIa with extended half-life
CA2656558A1 (en) * 2006-06-30 2008-01-10 The Regents Of The University Of Michigan Method of producing factor viii proteins by recombinant methods
US20090203077A1 (en) * 2006-06-30 2009-08-13 The Regents Of The University Of Michigan Method of producing factor viii proteins by recombinant methods
CA2673459C (en) 2006-12-22 2016-09-13 Stefan Schulte Modified coagulation factors with prolonged in vivo half-life
DK2865760T3 (en) 2008-06-24 2018-01-15 Csl Behring Gmbh Factor VIII, Von Willebrand Factor or complexes thereof with extended in vivo half-life
SG10201509149VA (en) * 2010-11-05 2015-12-30 Baxter Int A new variant of antihemophilic factor viii having increased specific activity
SI23610A (sl) 2011-01-13 2012-07-31 Diagen@d@o@o Nove adicijske soli ziprasidona postopek za njihovo pripravo in njihova uporaba v terapiji
EP2768521B1 (en) 2011-10-18 2016-07-13 CSL Behring GmbH Combined use of a sulfated glycosaminoglycan and a hyaluronidase for improving the bioavailability of factor viii
CN103889445A (zh) 2011-10-18 2014-06-25 德国杰特贝林生物制品有限公司 硫酸化糖胺聚糖用于改善因子viii的生物利用度的用途
CA2850579A1 (en) 2011-10-18 2013-04-25 Carsten Horn Method for improving the stability of purified factor viii after reconstitution
WO2013120939A1 (en) 2012-02-15 2013-08-22 Csl Behring Gmbh Von willebrand factor variants having improved factor viii binding affinity
WO2014041500A2 (en) * 2012-09-12 2014-03-20 Centre For Bioseparation Technology-Vit Double mutant coagulation factor viii and methods thereof
SG11201503719WA (en) * 2012-11-29 2015-06-29 Bayer Healthcare Llc MONOCLONAL ANTIBODIES AGAISNT ACTIVATED PROTEIN C (aPC)
US9657111B2 (en) 2012-11-29 2017-05-23 Bayer Healthcare Llc Humanized monoclonal antibodies against activated protein C and uses thereof
JP6523244B2 (ja) * 2013-03-15 2019-05-29 バイエル・ヘルスケア・エルエルシーＢａｙｅｒ ＨｅａｌｔｈＣａｒｅ ＬＬＣ 変異体第ｖｉｉｉ因子ポリペプチドならびにそれらの製造方法および使用方法
ES2657291T3 (es) 2013-04-22 2018-03-02 Csl Ltd. Un complejo covalente de factor de von Willebrand y factor VIII asociado por un puente disulfuro
EP3114138B1 (en) 2014-03-05 2021-11-17 Pfizer Inc. Improved muteins of clotting factor viii
BR112016030950A2 (pt) 2014-07-02 2018-03-27 Csl Ltd polipeptídeo modificado que se liga ao fator viii, complexo, composição farmacêutica, métodos para tratar uma coagulopatia, para produzir um polipeptídeo que compreende um vwf modificado e para aumentar a afinidade de ligação ao fator viii do vwf e a meia-vida do fator viii, uso de um polipeptídeo modificado ou de um complexo, polinucleotídeo, plasmídeo ou vetor, e, célula hospedeira.
DK3265489T3 (da) * 2015-03-06 2019-07-15 CSL Behring Lengnau AG Forbindelser til forbedring af halveringstiden af von willebrand faktor
CA2978374A1 (en) 2015-03-06 2016-09-15 Csl Behring Recombinant Facility Ag Modified von willebrand factor having improved half-life
US10772936B2 (en) 2015-05-22 2020-09-15 CSL Behring Lengnau AG Methods for preparing modified von Willebrand factor
SG10201910896UA (en) 2015-05-22 2020-01-30 CSL Behring Lengnau AG Truncated von willebrand factor polypeptides for treating hemophilia
US11077187B2 (en) 2015-11-17 2021-08-03 Oklahoma Medical Research Foundation Epitope of optimized humanized monoclonal antibodies against activated protein C and uses thereof
MX2018008337A (es) 2016-01-07 2018-09-17 CSL Behring Lengnau AG Factor de von willebrand truncado mutado.
AU2017205776B2 (en) 2016-01-07 2020-09-10 CSL Behring Lengnau AG Mutated von Willebrand factor
TW201828974A (zh) 2016-11-11 2018-08-16 瑞士商Ｃｓｌ貝林重組技能公司 用於血管外施予以治療或預防凝血疾病之截短型類血友病因子（ｖｏｎ Ｗｉｌｌｅｂｒａｎｄ ｆａｃｔｏｒ）多肽類
KR20190085021A (ko) 2016-11-11 2019-07-17 체에스엘 베링 렝나우 아게 혈우병을 치료하기 위한 절단된 폰 빌레브란트 인자 폴리펩타이드
EP3870206A4 (en) * 2018-10-23 2023-04-26 The Children's Hospital Of Philadelphia COMPOSITIONS AND METHODS OF MODULATION OF FACTOR VIII FUNCTION
US11471497B1 (en) 2019-03-13 2022-10-18 David Gordon Bermudes Copper chelation therapeutics
WO2021113800A1 (en) * 2019-12-06 2021-06-10 The Children's Hospital Of Philadelphia Compositions and methods for modulating factor viii function

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5214033A (en) 1983-03-31 1993-05-25 Scripps Clinic & Research Foundation Factor VIII coagulant polypeptides
US4757006A (en) 1983-10-28 1988-07-12 Genetics Institute, Inc. Human factor VIII:C gene and recombinant methods for production
US5045455A (en) 1984-01-12 1991-09-03 Chiron Corporation Factor VIII:C cDNA cloning and expression
SE8501050D0 (sv) 1985-03-05 1985-03-05 Kabivitrum Ab Biologically active fragments of human antihemophilic factor and method for preparation thereof
AU5772886A (en) 1985-04-12 1986-11-05 Genetics Institute Inc. Novel procoagulant proteins
JP2525022B2 (ja) 1986-01-03 1996-08-14 ジェネティックス・インスチチュ−ト・インコ−ポレ−テッド ▲ＶＩＩＩ▼：ｃ因子型タンパク質の改良生産方法
US5250421A (en) 1986-01-03 1993-10-05 Genetics Institute, Inc. Method for producing factor VIII:C-type proteins
AT388079B (de) 1986-04-18 1989-04-25 Helmut Ing Koenig Backofen
US5422260A (en) * 1986-05-29 1995-06-06 Genetics Institute, Inc. -Legal Affairs Human factor VIII:c muteins
US5451521A (en) * 1986-05-29 1995-09-19 Genetics Institute, Inc. Procoagulant proteins
US4912040A (en) 1986-11-14 1990-03-27 Genetics Institute, Inc. Eucaryotic expression system
CA1331157C (en) 1987-04-06 1994-08-02 Randal J. Kaufman Method for producing factor viii:c-type proteins
DE3720246A1 (de) 1987-06-19 1988-12-29 Behringwerke Ag Faktor viii:c-aehnliches molekuel mit koagulationsaktivitaet
US5004803A (en) 1988-11-14 1991-04-02 Genetics Institute, Inc. Production of procoagulant proteins
NZ236094A (en) 1989-11-17 1993-04-28 Chiron Corp Recombinant protein complex having human factor viii:c activity
US5661008A (en) 1991-03-15 1997-08-26 Kabi Pharmacia Ab Recombinant human factor VIII derivatives
US5563045A (en) 1992-11-13 1996-10-08 Genetics Institute, Inc. Chimeric procoagulant proteins
WO1997003194A1 (en) 1995-07-11 1997-01-30 Chiron Corporation Lysine 1689 factor viii:c polypeptide analogs
WO1997003195A1 (en) 1995-07-11 1997-01-30 Chiron Corporation Novel factor viii:c polypeptide analogs with altered protease sites
CA2252896C (en) * 1996-04-24 2009-03-10 The Regents Of The University Of Michigan Inactivation resistant factor viii

Also Published As

Publication number Publication date
DK1754718T3 (da) 2011-07-18
JP2007228973A (ja) 2007-09-13
US6838437B2 (en) 2005-01-04
EP1754718A3 (en) 2007-05-16
PT1754718E (pt) 2011-07-13
ATE319817T1 (de) 2006-03-15
DE69735421T2 (de) 2006-10-19
EP0910628A1 (en) 1999-04-28
DE69735421D1 (de) 2006-05-04
CA2252896A1 (en) 1997-10-30
JP3987114B2 (ja) 2007-10-03
US20060014683A1 (en) 2006-01-19
EP0910628A4 (en) 2001-05-02
AU3202797A (en) 1997-11-12
EP2202242A1 (en) 2010-06-30
EP1754718B1 (en) 2011-03-23
JP4250661B2 (ja) 2009-04-08
JP2000511407A (ja) 2000-09-05
WO1997040145A1 (en) 1997-10-30
EP1754718A2 (en) 2007-02-21
US7459534B2 (en) 2008-12-02
CA2252896C (en) 2009-03-10
EP0910628B1 (en) 2006-03-08
DE69740154D1 (de) 2011-05-05
US20020132306A1 (en) 2002-09-19

Similar Documents

Publication Publication Date Title
ATE319817T1 (de) Gegen inaktivierung resistenter faktor viii
DK0672138T3 (da) Kimære prokoagulante proteiner
DE69018920D1 (de) Verwendung von dns-fragmenten, die ein signalpeptid kodieren zur sekretion von reifen proteinen in rekombinanten hefen, expressions-kassetten, transformierte hefen und verfahren zur herstellung dieser proteine.
GEP20033002B (en) Osteoprotegerin Binding Protein and Receptors
ATE133681T1 (de) Mykobakterielle rekombinanten und peptide
EP0731636A4 (en) APOPTOSIS-MODULATING PROTEINS, DNA-ENCODING, AND METHOD FOR THEIR USE
DE69932599D1 (de) Künstliche chromosomen, die die genetische information für die bildung von rekombinantem virus enthalten
EP0205475A4 (en) RECOMBINANT METHOD FOR THE PRODUCTION OF SERINE PROTEASE INHIBITORS, AND DNA SEQUENCES THEREOF.
ATE286974T1 (de) Therapeutische domänen des von willebrand-faktor
ATE148992T1 (de) Zusammensetzungen zur hemmung der bildung von proteinhormon und deren verwendungen
MX9708426A (es) Polipeptido hk2 de variante estable.
ATE211390T1 (de) Überlegende thrombomodulinanaloga zur pharmazeutischen verwendung
DE59712235D1 (de) Immunologisch aktive proteine von borrelia burgdorferi, dafür kodierende nukleinsäuren sowie deren verwendung in testkits und als impfstoffe
SE9602822D0 (sv) New receptor
ATE190630T1 (de) Angiotensin-ii typ-1 rezeptor und dessen herstellung
DE69027967D1 (de) Proteine, die die expression von vertebraten-mhc-klasse-ii-genen regulieren, dafür kodierende dna-sequenzen und pharmazeutische zusammensetzungen
DE60124380D1 (de) Angiogenese-assoziierte proteine und dafür kodierende nukleinsäure
NO921219D0 (no) Somatostatin reseptor

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1754718

Country of ref document: EP